Family Medicine Lifestyle and Mind Medical Specialties News Preventive Health

Thailand says it expects coronavirus vaccine next year after tests in mice

Thailand expects to have a vaccine for the novel coronavirus ready next year, a senior official said on Wednesday, after finding positive trial results in mice.

Thailand will begin testing the mRNA (messenger RNA) vaccine in monkeys next week after successful trials in mice, said Taweesin Wisanuyothin, spokesman for the government’s Centre for COVID-19 Situation Administration.

“The Thai vaccine is expected to be used next year,” he said. More than 100 potential vaccines for COVID-19, the disease caused by the novel coronavirus, are being developed, including several in clinical trials, but the World Health Organization in April had warned that a vaccine would take at least 12 months.

The Thai vaccine is being developed by the National Vaccine Institute, the Department of Medical Science and Chulalongkorn University’s vaccine research centre.

Messenger RNA prompts body cells to produce so-called antigens, molecules on the surface of viruses, that spur the immune system into action.

Thailand was ranked fifth globally, just ahead of South Korea, for rapid response to and mitigation of the spread of an epidemic in the Johns Hopkins Global Health Security Index report in 2019.

U.S. drugmaker Moderna Inc’s experimental COVID-19 vaccine, the first to be tested in the United States, produced protective antibodies in a small group of healthy volunteers, according to very early data released by the company on Monday.

Drugmakers such as Johnson & Johnson and Pfizer Inc, which is working with Germany’s BioNTech SE, are also working to develop vaccines for the novel coronavirus.

Read More

Meeta Ramnani
Meeta Ramnani
Meeta develops credible content about various markets based on deep research, opinions from experts and inputs from industry leaders. As the managing editor at Smart Industry News, she assures that every piece of news and article adds to the knowledge of decision makers. An avid bike rider, Meeta, is a postgraduate from Indian Institute of Journalism and New Media (IIJNM) Bangalore, where her specialization was Business Journalism. She carries experience from mainstream print media including The Times Group and Sakal Media Group.
https://smarthealthcarenews.com/